The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with elevated eosinophil levels. Clinical trials show that Dupixent reduces COPD exacerbations and improves symptoms when combined with inhaled medications,

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of immune cells.